Education
About Us
Working with TipRanks
Follow Us
Klaria Pharma Holding AB (DE:6FN)
:6FN
6FN Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.01 - €0.15
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€5.78M
Enterprise Value€152.06M
Total Cash (Recent Filing)€598.00K
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta2.14
Next Earnings
Aug 28, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding144,758,770
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.46
Price to Book (P/B)1.76
Price to Sales (P/S)0.00
P/FCF Ratio-9.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
6FN FAQ
What was Klaria Pharma Holding AB’s price range in the past 12 months?
Klaria Pharma Holding AB lowest stock price was €0.01 and its highest was €0.15 in the past 12 months.
What is Klaria Pharma Holding AB’s market cap?
Klaria Pharma Holding AB’s market cap is €5.78M.
When is Klaria Pharma Holding AB’s upcoming earnings report date?
Klaria Pharma Holding AB’s upcoming earnings report date is Aug 28, 2025 which is in 70 days.
How were Klaria Pharma Holding AB’s earnings last quarter?
Klaria Pharma Holding AB released its earnings results on May 21, 2025. The company reported -€0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.001.
Is Klaria Pharma Holding AB overvalued?
According to Wall Street analysts Klaria Pharma Holding AB’s price is currently Overvalued.
Does Klaria Pharma Holding AB pay dividends?
Klaria Pharma Holding AB does not currently pay dividends.
What is Klaria Pharma Holding AB’s EPS estimate?
Klaria Pharma Holding AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Klaria Pharma Holding AB have?
Klaria Pharma Holding AB has 144,758,770 shares outstanding.
What happened to Klaria Pharma Holding AB’s price movement after its last earnings report?
Klaria Pharma Holding AB reported an EPS of -€0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Klaria Pharma Holding AB?
Currently, no hedge funds are holding shares in DE:6FN
Company Description
Klaria Pharma Holding AB
Klaria Pharma Holding AB (publ.) operates as a pharmaceutical company in Sweden and internationally. It offers Sumatriptan for the treatment of migraine; and Midazolam for acute epilepsy. The company's clinical phase products include Epinephrine/Adrenaline for the treatment of acute allergic reaction; Naloxone for opioid overdose; and Ketamine for acute pain and depression. It also focuses on the commercialization of cannabis/cannabinoids, including THC and CBD for medical and recreational applications. The company was founded in 2014 and is based in Uppsala, Sweden.
Technical Analysis
EQL Pharma AB
―
AlzeCure Pharma AB
―
Q-linea AB
―
NextCell Pharma AB
―
Neola Medical AB
―